Frank Siebenhaar

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9351371/publications.pdf

Version: 2024-02-01

80 papers	3,781 citations	117625 34 h-index	138484 58 g-index
86 all docs	86 docs citations	86 times ranked	3054 citing authors

#	Article	IF	Citations
1	A novel approach for studying mast cellâ€“driven disorders: Mast cells derived from induced pluripotent stem cells. Journal of Allergy and Clinical Immunology, 2022, 149, 1060-1068.e4.	2.9	9
2	The international EAACI/GAÂ²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 734-766.	5.7	392
3	Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases. Nature Reviews Immunology, 2022, 22, 294-308.	22.7	72
4	The Multifaceted Roles of Mast Cells in Immune Homeostasis, Infections and Cancers. International Journal of Molecular Sciences, 2022, 23, 2249.	4.1	17
5	Selected recent advances in understanding the role of human mast cells in health and disease. Journal of Allergy and Clinical Immunology, 2022, 149, 1833-1844.	2.9	26
6	Idiopathic mast cell activation syndrome is more often suspected than diagnosedâ€”A prospective realâ€life study. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2794-2802.	5.7	12
7	An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria. Journal of Allergy and Clinical Immunology, 2022, 149, 1683-1690.e7.	2.9	47
8	Mastocytoses. , 2022, , 1965-1972.		0
9	Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 2015-2024.	3.8	12
10	Total IgE as a Marker for Chronic Spontaneous Urticaria. Allergy, Asthma and Immunology Research, 2021, 13, 206.	2.9	55
11	Molecular Background, Clinical Features and Management of Pediatric Mastocytosis: Status 2021. International Journal of Molecular Sciences, 2021, 22, 2586.	4.1	38
12	Severe cold urticaria can point to an underlying clonal mast cell disorder. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2609-2613.	5.7	9
13	Lower IgA Levels in Chronic Spontaneous Urticaria Are Associated With Lower IgE Levels and Autoimmunity. Frontiers in Immunology, 2021, 12, 657211.	4.8	15
14	Mast Cells Modulate Antigen-Specific CD8+ T Cell Activation During LCMV Infection. Frontiers in Immunology, 2021, 12, 688347.	4.8	11
15	The Diagnostic Workup in Chronic Spontaneous Urticariaâ€”What to Test and Why. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2274-2283.	3.8	21
16	Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3918-3928.	3.8	33
17	COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM). Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2139-2144.	3.8	31
18	Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal. HemaSphere, 2021, 5, e646.	2.7	128

#	Article	IF	Citations
19	Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) in a phase 2 clinical study. Orphanet Journal of Rare Diseases, 2021, 16, 434.	2.7	5
20	Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAFÂ©. Orphanet Journal of Rare Diseases, 2021, 16, 414.	2.7	8
21	Development of the Angioedema Control Testâ€"A patientâ€reported outcome measure that assesses disease control in patients with recurrent angioedema. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1165-1177.	5.7	47
22	Translation and Cultural Adaptation of the German Mastocytosis Quality of Life Questionnaire (MC-QoL) Into Spanish. Actas Dermo-sifiliogrÃ¡ficas, 2020, 111, 243-248.	0.4	0
23	Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine. International Journal of Molecular Sciences, 2020, 21, 9030.	4.1	56
24	In vivo non-invasive staining-free visualization of dermal mast cells in healthy, allergy and mastocytosis humans using two-photon fluorescence lifetime imaging. Scientific Reports, 2020, 10, 14930.	3.3	21
25	Validation of the Angioedema Control Test (AECT)â€"A Patient-Reported Outcome Instrument for Assessing Angioedema Control. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2050-2057.e4.	3.8	50
26	Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions. Journal of Allergy and Clinical Immunology, 2020, 146, 300-306.	2.9	23
27	AdaptaciÃ³n transcultural del cuestionario Mastocytosis Quality of Life questionnaire (MC-QoL) del alemÃ¡n al castellano. Actas Dermo-sifiliogrÃ¡ficas, 2020, 111, 243-248.	0.4	2
28	Generation and Culture of Peripheral CD34+ Stem Cell-Derived Mast Cells (PSCMCs). Methods in Molecular Biology, 2020, 2163, 63-67.	0.9	3
29	Mastocytoses. , 2020, , 1-8.		0
30	Mast Cell-Mediated Reactions In Vivo. Methods in Molecular Biology, 2020, 2163, 357-365.	0.9	0
31	The Henna pigment Lawsone activates the Aryl Hydrocarbon Receptor and impacts skin homeostasis. Scientific Reports, 2019, 9, 10878.	3.3	17
32	Chymase-Cre; Mcl-1fl/fl Mice Exhibit Reduced Numbers of Mucosal Mast Cells. Frontiers in Immunology, 2019, 10, 2399.	4.8	9
33	Effective treatment of a lymphocytic variant of hypereosinophilic syndrome with reslizumab. JDDG - Journal of the German Society of Dermatology, 2019, 17, 1171-1172.	0.8	4
34	Mast cells drive IgE-mediated disease but might be bystanders in many other inflammatory and neoplastic conditions. Journal of Allergy and Clinical Immunology, 2019, 144, S19-S30.	2.9	24
35	Detection of KIT D816V mutation in patients with severe anaphylaxis and normal basal tryptaseâ€"first data from the Anaphylaxis Registry (NORA). Journal of Allergy and Clinical Immunology, 2019, 144, 1448-1450.e1.	2.9	13
36	Mast cells are critical for controlling the bacterial burden and the healing of infected wounds. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 20500-20504.	7.1	55

#	Article	IF	Citations
37	Diagnosis and treatment of chronic inducible urticaria. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2550-2553.	5.7	26
38	Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1125-1133.e1.	3.8	150
39	Development and validation of the mastocytosis activity score. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 1489-1496.	5.7	17
40	Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 230-238.	5.7	88
41	Development of tripe palms and soles in a patient with long preâ€existing systemic mastocytosis and newly developed nonâ€small cell lung cancer. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e151-e153.	2.4	0
42	Mast Cells as Drivers of Disease and Therapeutic Targets. Trends in Immunology, 2018, 39, 151-162.	6.8	103
43	Chronische Urtikaria â€“ Was bringt die neue Leitlinie?. JDDG - Journal of the German Society of Dermatology, 2018, 16, 585-595.	0.8	6
44	Chronic urticaria â€“ What does the new guideline tell us?. JDDG - Journal of the German Society of Dermatology, 2018, 16, 584-593.	0.8	17
45	Mastozytose. , 2018, , 1979-1985.		0
46	Clinical Measures of Chronic Urticaria. Immunology and Allergy Clinics of North America, 2017, 37, 35-49.	1.9	34
47	Histamine intolerance in patients with chronic spontaneous urticaria. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1774-1777.	2.4	29
48	Development and validation of the mastocytosis quality of life questionnaire: MC-QoL. Allergy: European Journal of Allergy and Clinical Immunology, 2016, 71, 869-877.	5.7	45
49	Controversies and challenges in the management of chronic urticaria. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 16-24.	2.4	9
50	The male beard hair and facial skin â€“ challenges for shaving. International Journal of Cosmetic Science, 2016, 38, 3-9.	2.6	9
51	Innovative approaches to avoid electric shavingâ€induced skin irritation. International Journal of Cosmetic Science, 2016, 38, 10-16.	2.6	6
52	Questions and answers in chronic urticaria: where do we stand and where do we go?. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 7-15.	2.4	22
53	Mast Cells Limit the Exacerbation of Chronic Allergic Contact Dermatitis in Response to Repeated Allergen Exposure. Journal of Immunology, 2016, 197, 4240-4246.	0.8	50
54	Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. Journal of Allergy and Clinical Immunology, 2016, 137, 35-45.	2.9	289

#	Article	IF	Citations
55	Murine and human mast cell progenitors. European Journal of Pharmacology, 2016, 778, 2-10.	3.5	30
56	Mastozytose. , 2016, , 1-7.		0
57	An improved Peltier effectâ€based instrument for critical temperature threshold measurement in coldâ€• and heatâ€induced urticaria. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2043-2045.	2.4	35
58	Recognizing mastocytosis in patients with anaphylaxis: Value of KIT D816V mutation analysis of peripheral blood. Journal of Allergy and Clinical Immunology, 2015, 135, 262-264.	2.9	47
59	Mast Cell-Mediated and Associated Disorders in Pregnancy: A Risky Game with an Uncertain Outcome?. Frontiers in Immunology, 2014, 5, 231.	4.8	37
60	Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 1267-1274.	5.7	139
61	Mast cells protect from skin tumor development and limit tumor growth during cutaneous de novo carcinogenesis in a <scp>K</scp>itâ€dependent mouse model. Experimental Dermatology, 2014, 23, 159-164.	2.9	27
62	A novel method to generate and culture human mast cells: Peripheral CD34+ stem cell-derived mast cells (PSCMCs). Journal of Immunological Methods, 2014, 413, 62-68.	1.4	37
63	Treatment Strategies in Mastocytosis. Immunology and Allergy Clinics of North America, 2014, 34, 433-447.	1.9	53
64	Miltefosine: a novel treatment option for mast cell-mediated diseases. Journal of Dermatological Treatment, 2013, 24, 244-249.	2.2	10
65	Randomized, doubleâ€blind, placeboâ€controlled study of safety and efficacy of miltefosine in antihistamineâ€resistant chronic spontaneous urticaria. Journal of the European Academy of Dermatology and Venereology, 2013, 27, e363-9.	2.4	23
66	Anaphylaxis caused by mosquito allergy in systemic mastocytosis. Lancet, The, 2013, 382, 1380.	13.7	35
67	Rupatadine improves quality of life in mastocytosis: a randomized, doubleâ€blind, placeboâ€controlled trial. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 949-952.	5.7	46
68	Practical algorithm for diagnosing patients with recurrent wheals or angioedema. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 816-819.	5.7	53
69	European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. Wiener Klinische Wochenschrift, 2012, 124, 807-814.	1.9	33
70	Anti-Immunoglobulin E Treatment of Patients with Recalcitrant Physical Urticaria. International Archives of Allergy and Immunology, 2011, 154, 177-180.	2.1	133
71	H1-Antihistamine Up-Dosing in Chronic Spontaneous Urticaria: Patients' Perspective of Effectiveness and Side Effects â€“ A Retrospective Survey Study. PLoS ONE, 2011, 6, e23931.	2.5	47
72	Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trial. British Journal of Dermatology, 2010, 162, 185-190.	1.5	19

#	Article	IF	Citations
73	Antihistamineâ€resistant urticaria factitia successfully treated with antiâ€immunoglobulin E therapy. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1494-1495.	5.7	46
74	High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: A randomized, placebo-controlled, crossover study. Journal of Allergy and Clinical Immunology, 2009, 123, 672-679.	2.9	187
75	Mast cellâ€“driven skin inflammation is impaired in the absence of sensory nerves. Journal of Allergy and Clinical Immunology, 2008, 121, 955-961.	2.9	75
76	Mast cell functions in the innate skin immune system. Immunobiology, 2008, 213, 251-260.	1.9	104
77	Control of Pseudomonas aeruginosa Skin Infections in Mice Is Mast Cell-Dependent. American Journal of Pathology, 2007, 170, 1910-1916.	3.8	80
78	Successful treatment of cutaneous mastocytosis and MÃ©niÃ¨re disease with anti-IgE therapy. Journal of Allergy and Clinical Immunology, 2007, 120, 213-215.	2.9	57
79	Acquired cold urticaria: clinical picture and update on diagnosis and treatment. Clinical and Experimental Dermatology, 2007, 32, 241-245.	1.3	105
80	Skin mast cells control T cellâ€dependent host defense in Leishmania major infections. FASEB Journal, 2006, 20, 2460-2467.	0.5	123